Steroid-Sensitive Genetic FSGS Associated with a CD2AP Variant Achieving Sustained Remission After Rituximab: A Sibling Case Series (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0134; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Although genetic FSGS is often considered non-immune, our observations suggest phenotypic heterogeneity and potential benefit of rituximab in selected patients. Sustained remission after single-dose rituximab with minimal ongoing immunosuppression challenges traditional therapeutic nihilism in genetic podocytopathies and supports incorporating genetic testing into management and counseling strategies."
Clinical • Chronic Kidney Disease • Focal Segmental Glomerulosclerosis • Gene Therapies • Glomerulonephritis • Nephrology • Renal Disease • CD2 • CD2AP
|
|
Hany Tobia Michael; Abdurrahman M. Hamadah; Fakhriya Juma Abdulla Alalawi; Malaz Noralla Soliman; Amna Khalifa Alhadari
|